AI assistant
Innate Pharma — Investor Presentation 2026
Feb 18, 2026
1440_iss_2026-02-18_7f4ea6f7-8520-4c07-9342-8962ce947b77.pdf
Investor Presentation
Open in viewerOpens in your device viewer
PRESS RELEASE
innate pharma
INNATE PHARMA TO PARTICIPATE IN THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE
Marseille, France, February 18, 2026, 7:00 AM CET
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference:
Leerink Partners Global Healthcare Conference 2026
- Dates: March 8–11, 2026
- Location: Miami, Florida, United States
Fireside chat:
- Date: March 9, 2026
- Time: 3:40 PM ET / 8:40 PM CET
- To enter the live webcast, please click here
The link to access the live webcast of the presentation will be available on the Events page of the Investors section of Innate Pharma’s website. A replay of the presentation will be available following the event.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.
Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Page 1/2
PRESS RELEASE
innate pharma
Information about Innate Pharma shares
ISIN code
TR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors
For a discussion of risks and uncertainties, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Investors & Media Relations
Innate Pharma
Stéphanie Cornen
[email protected]
Investor Relations
[email protected]
Media
[email protected]
Page 2/2